Dendritic Cell Cancer Vaccine Market Projected to Reach $1,760.6 Million by 2035

Dendritic Cell Cancer Vaccine market was valued at $600.5 million in 2025 and is projected to reach $1,760.6 million by 2035, growing at a CAGR of 11.4% during the forecast period (2026-2035).The rising global burden of cancer is a fundamental driver for the growth of the dendritic cell cancer vaccine market. Increasing cancer prevalence directly expands the addressable patient pool, thereby accelerating demand for advanced and targeted treatment approaches. Epidemiological trends indicate a continuous surge in cancer diagnoses across major regions, reinforcing the need for innovative therapies. For instance, China reports nearly 5 million new cancer cases annually, accounting for approximately one-quarter of global diagnoses, with oncology representing a significant share of its research and development pipeline. Similarly, the United States recorded over 2 million new cancer cases in 2024, averaging around 5,480 diagnoses per day, highlighting the scale of unmet clinical demand. In the United Kingdom, approximately 3.5 million individuals are living with cancer, with more than 420,000 new cases reported each year. In India, cancers such as oral and lung in males, and cervical and breast in females, contribute to more than half of the total cancer burden, indicating a high need for effective treatment solutions.

Browse the full report description of “Dendritic Cell Cancer Vaccine Market Size, Share & Trends Analysis Report by Product Type (SipuleucelT (Provenge), CreaVax, Autologous, Allogeneic, and Other), by Indication (Prostate Cancer, Melanoma, Glioblastoma, Renal Cell, Carcinoma, Breast Cancer, and Other Solid Tumors), by EndUser (Hospitals, Specialty Oncology Clinics, Academic & Research Institutes, and Cancer Treatment Centers), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/dendritic-cell-cancer-vaccine-market

This growing disease burden underscores the limitations of conventional therapies such as chemotherapy and radiation, which are often associated with significant toxicity and suboptimal efficacy in certain cancer types. As a result, there is a strong clinical shift toward safer and more targeted treatment modalities. Dendritic cell cancer vaccines, as a form of personalized immunotherapy, offer the potential to stimulate the patient’s immune system to recognize and attack tumor cells with greater specificity. The increasing incidence of cancer is therefore not only expanding the patient base but also intensifying the demand for novel therapeutic alternatives. Consequently, the convergence of rising cancer cases and the need for improved treatment outcomes is expected to significantly propel the adoption of dendritic cell cancer vaccines in the global market.

Strategic Developments and Clinical Advancements

The major companies operating in the global dendritic cell cancer vaccine market include Argos Therapeutics Inc., Dendreon Pharmaceuticals LLC, EOM Pharmaceutical Inc., Northwest Biotherapeutics, Inc., Medigene AG, among others. These major players are actively focusing on advancing clinical pipelines, investing in personalized immunotherapy platforms, and strengthening their positions through strategic funding and regulatory designations to accelerate product development and commercialization.

• In March 2026, Diakonos Oncology announced it will present new clinical data on its investigational immunotherapy DOC1021 (dubodencel) at the AACR Annual Meeting and the American Academy of Neurology Annual Meeting. The presentations will highlight results in pancreatic cancer and glioblastoma, respectively, evaluating the therapy’s ability to stimulate immune responses using patient-derived dendritic cells. DOC1021 is currently being studied in multiple clinical trials and has received FDA Fast Track and Orphan Drug designations for these indications.

• In June 2025, Diakonos Oncology raised $20 million through a private SAFE financing to support its Phase II clinical trial of dubodencel (DOC1021) for glioblastoma. The funding, backed by investors including Baylor College of Medicine, will also support expansion into additional indications such as refractory melanoma. Dubodencel is a patient-derived dendritic cell therapy designed to stimulate immune response against tumors and has received FDA Fast Track and Orphan Drug designations for certain cancer programs.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Product Type
• Indication
• End?User
• Competitive Landscape – Argos Therapeutics Inc., Dendreon Pharmaceuticals LLC, EOM Pharmaceutical Inc., Northwest Biotherapeutics, Inc., Medigene AG.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dendritic Cell Cancer Vaccine Market Report Segment

By Product Type

• Sipuleucel?T (Provenge)
• CreaVax
• Autologous
• Allogeneic
• Other

By Indication

• Prostate Cancer
• Melanoma
• Glioblastoma
• Renal Cell Carcinoma
• Breast Cancer
• Other Solid Tumors

By Distribution Channel

• Hospitals
• Specialty Oncology Clinics
• Academic & Research Institutes
• Cancer Treatment Centers

Global Dendritic Cell Cancer Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dendritic-cell-cancer-vaccine-market